Global Head Lice Infestation Treatment Market

Head Lice Infestation Treatment Comprehensive Study by Type (Lotion, Creams, Shampoo), Treatment Type (Topical Pediculicides (Malathion, Permethrin), Wet Combing, Oral Therapy), End User (Childrens, Adults) Players and Region - Global Market Outlook to 2027

Head Lice Infestation Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Head Lice Infestation Treatment
Head lice are small wingless biting insects that live and breed in human hair and feed by sucking blood from the scalp. Outbreaks of head lice are common in children in schools and institutions everywhere. They infest people of all socio-economic positions and age groups. Head lice infestation is widespread, affecting both children and adults. In the United States, it is estimated that between 6 and 12 million infestations occur each year among children 3 to 11 years of age. This has risen the demand for Head Lice Infestation Treatment.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


In Head Lice Infestation Treatment Market, it has been observed that most of the companies are upgrading or introducing innovative products. They rely on strategies such as mergers & acquisitions, product development, geographical expansion, technological innovation and sourcing strategies to enhance their market share. Analyst at AMA Research estimates that United States and European Players will contribute the maximum growth to Global Head Lice Infestation Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Actavis Generics (United States), Thornton & Ross Ltd. (United Kingdom), Omega Pharma (Belgium), Prestige Brands Holdings, Inc. (United States), Perrigo Company plc (Ireland), Bayer AG (Germany), Logic Product Group, LLC (United States), Major Pharmaceuticals, Inc. (United States), Reckitt Benckier Group plc (United Kingdom), Arbor Pharmaceuticals, LLC (United States), Shionogi & Company, Limited (Japan) and Tyratech, Inc, (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Head Lice Infestation Treatment market by Type (Lotion, Creams and Shampoo) and Region.



On the basis of geography, the market of Head Lice Infestation Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Topical Pediculicides [Malathion, Permethrin] will boost the Head Lice Infestation Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Childrens will boost the Head Lice Infestation Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Number of Patients in Asian Countries

Market Growth Drivers:
Growing Rate of Head Lice Among Children Aged 4–11 Years and Preference for Wet Combing Treatment

Challenges:
After taking treatment if interacted with water it may reduce its effect.

Restraints:
May Cause Side Effect for People with Sensitive Skin or Dermatitis.

Opportunities:
Growing Use of Pediculicides for Head Lice Treatment and Growing Demand from Emerging Countries

In July 2020, Omega Therapeutics is getting a USD 85 million cash boost. It will push a pipeline of treatments toward the clinic as well as bankroll the identification of new targets for genomic medicines.
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ‘‘Head Lice Infestation: Developing Drugs for Topical Treatment.’’ The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of head lice infestation. This draft guidance addresses the Agency’s current thinking regarding the overall development program and clinical trial designs of drugs to support approval of an indication for topical treatment of head lice infestation.

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Head Lice Infestation Treatment Providers, Raw Material Suppliers, Dealers, Suppliers, Traders and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End User Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Lotion
  • Creams
  • Shampoo
By Treatment Type
  • Topical Pediculicides [Malathion, Permethrin]
  • Wet Combing
  • Oral Therapy

By End User
  • Childrens
  • Adults

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Rate of Head Lice Among Children Aged 4–11 Years
      • 3.2.2. Preference for Wet Combing Treatment
    • 3.3. Market Challenges
      • 3.3.1. After taking treatment if interacted with water it may reduce its effect.
    • 3.4. Market Trends
      • 3.4.1. Growing Number of Patients in Asian Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Head Lice Infestation Treatment, by Type, Treatment Type, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Head Lice Infestation Treatment (Value)
      • 5.2.1. Global Head Lice Infestation Treatment by: Type (Value)
        • 5.2.1.1. Lotion
        • 5.2.1.2. Creams
        • 5.2.1.3. Shampoo
      • 5.2.2. Global Head Lice Infestation Treatment by: Treatment Type (Value)
        • 5.2.2.1. Topical Pediculicides [Malathion, Permethrin]
        • 5.2.2.2. Wet Combing
        • 5.2.2.3. Oral Therapy
      • 5.2.3. Global Head Lice Infestation Treatment by: End User (Value)
        • 5.2.3.1. Childrens
        • 5.2.3.2. Adults
      • 5.2.4. Global Head Lice Infestation Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Head Lice Infestation Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Actavis Generics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thornton & Ross Ltd. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Omega Pharma (Belgium)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Prestige Brands Holdings, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Perrigo Company plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Logic Product Group, LLC (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Major Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Reckitt Benckier Group plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Arbor Pharmaceuticals, LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Shionogi & Company, Limited (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Tyratech, Inc, (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Head Lice Infestation Treatment Sale, by Type, Treatment Type, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Head Lice Infestation Treatment (Value)
      • 7.2.1. Global Head Lice Infestation Treatment by: Type (Value)
        • 7.2.1.1. Lotion
        • 7.2.1.2. Creams
        • 7.2.1.3. Shampoo
      • 7.2.2. Global Head Lice Infestation Treatment by: Treatment Type (Value)
        • 7.2.2.1. Topical Pediculicides [Malathion, Permethrin]
        • 7.2.2.2. Wet Combing
        • 7.2.2.3. Oral Therapy
      • 7.2.3. Global Head Lice Infestation Treatment by: End User (Value)
        • 7.2.3.1. Childrens
        • 7.2.3.2. Adults
      • 7.2.4. Global Head Lice Infestation Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Head Lice Infestation Treatment: by Type(USD Million)
  • Table 2. Head Lice Infestation Treatment Lotion , by Region USD Million (2016-2021)
  • Table 3. Head Lice Infestation Treatment Creams , by Region USD Million (2016-2021)
  • Table 4. Head Lice Infestation Treatment Shampoo , by Region USD Million (2016-2021)
  • Table 5. Head Lice Infestation Treatment: by Treatment Type(USD Million)
  • Table 6. Head Lice Infestation Treatment Topical Pediculicides [Malathion, Permethrin] , by Region USD Million (2016-2021)
  • Table 7. Head Lice Infestation Treatment Wet Combing , by Region USD Million (2016-2021)
  • Table 8. Head Lice Infestation Treatment Oral Therapy , by Region USD Million (2016-2021)
  • Table 9. Head Lice Infestation Treatment: by End User(USD Million)
  • Table 10. Head Lice Infestation Treatment Childrens , by Region USD Million (2016-2021)
  • Table 11. Head Lice Infestation Treatment Adults , by Region USD Million (2016-2021)
  • Table 12. South America Head Lice Infestation Treatment, by Country USD Million (2016-2021)
  • Table 13. South America Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 14. South America Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 15. South America Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 16. Brazil Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 17. Brazil Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 18. Brazil Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 19. Argentina Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 20. Argentina Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 21. Argentina Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 22. Rest of South America Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 23. Rest of South America Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 24. Rest of South America Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 25. Asia Pacific Head Lice Infestation Treatment, by Country USD Million (2016-2021)
  • Table 26. Asia Pacific Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 27. Asia Pacific Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 28. Asia Pacific Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 29. China Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 30. China Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 31. China Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 32. Japan Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 33. Japan Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 34. Japan Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 35. India Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 36. India Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 37. India Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 38. South Korea Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 39. South Korea Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 40. South Korea Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 41. Taiwan Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 42. Taiwan Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 43. Taiwan Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 44. Australia Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 45. Australia Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 46. Australia Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 50. Europe Head Lice Infestation Treatment, by Country USD Million (2016-2021)
  • Table 51. Europe Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 52. Europe Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 53. Europe Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 54. Germany Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 55. Germany Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 56. Germany Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 57. France Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 58. France Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 59. France Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 60. Italy Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 61. Italy Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 62. Italy Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 63. United Kingdom Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 64. United Kingdom Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 65. United Kingdom Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 66. Netherlands Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 67. Netherlands Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 68. Netherlands Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 69. Rest of Europe Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 70. Rest of Europe Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 71. Rest of Europe Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 72. MEA Head Lice Infestation Treatment, by Country USD Million (2016-2021)
  • Table 73. MEA Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 74. MEA Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 75. MEA Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 76. Middle East Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 77. Middle East Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 78. Middle East Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 79. Africa Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 80. Africa Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 81. Africa Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 82. North America Head Lice Infestation Treatment, by Country USD Million (2016-2021)
  • Table 83. North America Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 84. North America Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 85. North America Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 86. United States Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 87. United States Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 88. United States Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 89. Canada Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 90. Canada Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 91. Canada Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 92. Mexico Head Lice Infestation Treatment, by Type USD Million (2016-2021)
  • Table 93. Mexico Head Lice Infestation Treatment, by Treatment Type USD Million (2016-2021)
  • Table 94. Mexico Head Lice Infestation Treatment, by End User USD Million (2016-2021)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Head Lice Infestation Treatment: by Type(USD Million)
  • Table 108. Head Lice Infestation Treatment Lotion , by Region USD Million (2022-2027)
  • Table 109. Head Lice Infestation Treatment Creams , by Region USD Million (2022-2027)
  • Table 110. Head Lice Infestation Treatment Shampoo , by Region USD Million (2022-2027)
  • Table 111. Head Lice Infestation Treatment: by Treatment Type(USD Million)
  • Table 112. Head Lice Infestation Treatment Topical Pediculicides [Malathion, Permethrin] , by Region USD Million (2022-2027)
  • Table 113. Head Lice Infestation Treatment Wet Combing , by Region USD Million (2022-2027)
  • Table 114. Head Lice Infestation Treatment Oral Therapy , by Region USD Million (2022-2027)
  • Table 115. Head Lice Infestation Treatment: by End User(USD Million)
  • Table 116. Head Lice Infestation Treatment Childrens , by Region USD Million (2022-2027)
  • Table 117. Head Lice Infestation Treatment Adults , by Region USD Million (2022-2027)
  • Table 118. South America Head Lice Infestation Treatment, by Country USD Million (2022-2027)
  • Table 119. South America Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 120. South America Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 121. South America Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 122. Brazil Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 123. Brazil Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 124. Brazil Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 125. Argentina Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 126. Argentina Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 127. Argentina Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 128. Rest of South America Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 129. Rest of South America Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 130. Rest of South America Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 131. Asia Pacific Head Lice Infestation Treatment, by Country USD Million (2022-2027)
  • Table 132. Asia Pacific Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 133. Asia Pacific Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 134. Asia Pacific Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 135. China Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 136. China Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 137. China Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 138. Japan Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 139. Japan Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 140. Japan Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 141. India Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 142. India Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 143. India Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 144. South Korea Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 145. South Korea Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 146. South Korea Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 147. Taiwan Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 148. Taiwan Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 149. Taiwan Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 150. Australia Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 151. Australia Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 152. Australia Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 153. Rest of Asia-Pacific Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 156. Europe Head Lice Infestation Treatment, by Country USD Million (2022-2027)
  • Table 157. Europe Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 158. Europe Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 159. Europe Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 160. Germany Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 161. Germany Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 162. Germany Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 163. France Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 164. France Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 165. France Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 166. Italy Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 167. Italy Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 168. Italy Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 169. United Kingdom Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 170. United Kingdom Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 171. United Kingdom Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 172. Netherlands Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 173. Netherlands Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 174. Netherlands Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 175. Rest of Europe Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 176. Rest of Europe Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 177. Rest of Europe Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 178. MEA Head Lice Infestation Treatment, by Country USD Million (2022-2027)
  • Table 179. MEA Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 180. MEA Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 181. MEA Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 182. Middle East Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 183. Middle East Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 184. Middle East Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 185. Africa Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 186. Africa Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 187. Africa Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 188. North America Head Lice Infestation Treatment, by Country USD Million (2022-2027)
  • Table 189. North America Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 190. North America Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 191. North America Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 192. United States Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 193. United States Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 194. United States Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 195. Canada Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 196. Canada Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 197. Canada Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 198. Mexico Head Lice Infestation Treatment, by Type USD Million (2022-2027)
  • Table 199. Mexico Head Lice Infestation Treatment, by Treatment Type USD Million (2022-2027)
  • Table 200. Mexico Head Lice Infestation Treatment, by End User USD Million (2022-2027)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Head Lice Infestation Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Head Lice Infestation Treatment: by Treatment Type USD Million (2016-2021)
  • Figure 6. Global Head Lice Infestation Treatment: by End User USD Million (2016-2021)
  • Figure 7. South America Head Lice Infestation Treatment Share (%), by Country
  • Figure 8. Asia Pacific Head Lice Infestation Treatment Share (%), by Country
  • Figure 9. Europe Head Lice Infestation Treatment Share (%), by Country
  • Figure 10. MEA Head Lice Infestation Treatment Share (%), by Country
  • Figure 11. North America Head Lice Infestation Treatment Share (%), by Country
  • Figure 12. Global Head Lice Infestation Treatment share by Players 2021 (%)
  • Figure 13. Global Head Lice Infestation Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Head Lice Infestation Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Actavis Generics (United States) Revenue, Net Income and Gross profit
  • Figure 17. Actavis Generics (United States) Revenue: by Geography 2021
  • Figure 18. Thornton & Ross Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Thornton & Ross Ltd. (United Kingdom) Revenue: by Geography 2021
  • Figure 20. Omega Pharma (Belgium) Revenue, Net Income and Gross profit
  • Figure 21. Omega Pharma (Belgium) Revenue: by Geography 2021
  • Figure 22. Prestige Brands Holdings, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Prestige Brands Holdings, Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Perrigo Company plc (Ireland) Revenue: by Geography 2021
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 28. Logic Product Group, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 29. Logic Product Group, LLC (United States) Revenue: by Geography 2021
  • Figure 30. Major Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Major Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 32. Reckitt Benckier Group plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Reckitt Benckier Group plc (United Kingdom) Revenue: by Geography 2021
  • Figure 34. Arbor Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 35. Arbor Pharmaceuticals, LLC (United States) Revenue: by Geography 2021
  • Figure 36. Shionogi & Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Shionogi & Company, Limited (Japan) Revenue: by Geography 2021
  • Figure 38. Tyratech, Inc, (United States) Revenue, Net Income and Gross profit
  • Figure 39. Tyratech, Inc, (United States) Revenue: by Geography 2021
  • Figure 40. Global Head Lice Infestation Treatment: by Type USD Million (2022-2027)
  • Figure 41. Global Head Lice Infestation Treatment: by Treatment Type USD Million (2022-2027)
  • Figure 42. Global Head Lice Infestation Treatment: by End User USD Million (2022-2027)
  • Figure 43. South America Head Lice Infestation Treatment Share (%), by Country
  • Figure 44. Asia Pacific Head Lice Infestation Treatment Share (%), by Country
  • Figure 45. Europe Head Lice Infestation Treatment Share (%), by Country
  • Figure 46. MEA Head Lice Infestation Treatment Share (%), by Country
  • Figure 47. North America Head Lice Infestation Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Actavis Generics (United States)
  • Thornton & Ross Ltd. (United Kingdom)
  • Omega Pharma (Belgium)
  • Prestige Brands Holdings, Inc. (United States)
  • Perrigo Company plc (Ireland)
  • Bayer AG (Germany)
  • Logic Product Group, LLC (United States)
  • Major Pharmaceuticals, Inc. (United States)
  • Reckitt Benckier Group plc (United Kingdom)
  • Arbor Pharmaceuticals, LLC (United States)
  • Shionogi & Company, Limited (Japan)
  • Tyratech, Inc, (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 156 Pages 94 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Head Lice Infestation Treatment Market Quantitative research analysis
Global Head Lice Infestation Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Actavis Generics (United States), Thornton & Ross Ltd. (United Kingdom), Omega Pharma (Belgium), Prestige Brands Holdings, Inc. (United States), Perrigo Company plc (Ireland), Bayer AG (Germany), Logic Product Group, LLC (United States), Major Pharmaceuticals, Inc. (United States), Reckitt Benckier Group plc (United Kingdom), Arbor Pharmaceuticals, LLC (United States), Shionogi & Company, Limited (Japan) and Tyratech, Inc, (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Number of Patients in Asian Countries" is seen as one of major influencing trends for Head Lice Infestation Treatment Market during projected period 2021-2027.
The Head Lice Infestation Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Head Lice Infestation Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Nutrigenomics Testing Comprehensive Study by Application (Obesity, Diabetes, Cardiovascular Diseases, Cancer Research, Women's Health, Neurological, Others), Distribution Channel (Hospitals & Clinics...
$ 3500
Ayurveda Comprehensive Study by Application (Gastrointestinal Diseases, Cardiac Disorders, Respiratory Disorders, Psychological Disorders, Movement Disorders, Others), Treatment (Vamana, Virechana, N...
$ 3650
Single Cell Isolation Systems Comprehensive Study by Type (Flow Cytometry Systems, Microfluidic Systems, Laser Microdissection Systems, Others), Application (Drug Discovery, Life Science Research, Ot...
$ 3450
Elderly Care Facilities Comprehensive Study by Type (Pharmaceuticals, Housing and Assistive Devices), Application (Heart Diseases, Cancer, Kidney Diseases, Diabetes, Arthritis, Osteoporosis, Neurolog...
$ 3750
Hematology Therapies Comprehensive Study by Type (Instruments, Consumable), Application (Physiology, Pathology, Etiology, Diagnosis, Treatment, Prognosis), Blood Disorder Type (Hemophilia, Leukemia, ...
$ 3650
Healthcare and Hospital Room Furniture Comprehensive Study by Type (Chairs, Beds, Tables, Others), Application (Physicians Furniture, Patient Furniture, Staff Furniture), Department (Day Care, Emerge...
$ 3450